PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSI...

por Daver, N. G., Wei, A. H., Stein, E. M., DeAngelo, D. J., Pathak, D., Xu, Y., Grzesiak, S., Venditti, A.
Publicado 2022

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS

por Rajakumaraswamy, N., Gandhi, M., Wei, A. H., Sallman, D. A., Daver, N. G., Mo, S., Iqbal, S., Chen, M., Wang, Y., Vyas, P.
Publicado 2022

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy

por DiNardo, CD, Daver, N, Jain, N, Pemmaraju, N, Bueso-Ramos, C, Yin, CC, Pierce, S, Jabbour, E, Cortes, JE, Kantarjian, HM, Garcia-Manero, G, Verstovsek, S
Publicado 2014

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)

por Ong, F., Kadia, T. M., Short, N. J., Yilmaz, M., Alvarado, Y., Pierce, S., Garcia-Manero, G., DiNardo, C., Borthakur, G., Konopleva, M., Daver, N., Kantarjian, H., Ravandi, F.
Publicado 2022

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WIT...

por Daver, N., Maris, M., Ramchandren, R., Bixby, D., Doucette, K., Mawad, R., Egan, D., Stevens, D., Zonder, J., Molloy, N., Scheuber, A., Bruns, I., Mantzaris, I., Konopleva, M., Goldberg, A. D.
Publicado 2022

P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A P...

por Yacoub, A., Borate, U., Rampal, R., Ali, H., Wang, E., Gerds, A., Hobbs, G., Kremyanskaya, M., Winton, E., O’Connell, C., Goel, S., Oh, S., Schiller, G., Assad, A., Erickson-Viitanen, S., Zhou, F., Daver, N.
Publicado 2022

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE...

por Daver, N. G., Vyas, P., Kambhampati, S., Al Malki, M. M., Larson, R., Asch, A., Mannis, G., Chai-Ho, W., Tanaka, T., Bradley, T., Jeyakumar, D., Wang, E., Xing, G., Chao, M., Ramsingh, G., Renard, C., Lal, I., Zeidner, J., Sallman, D.
Publicado 2022

P1203: THE OPTIMIZED HLH INFLAMMATORY (OHI) INDEX IDENTIFIES LYMPHOMA PATIENTS WITH UNEXPECTEDLY HIGH MORTALITY NOT RELATED TO DISEASE PROGRESSION

por Zoref-Lorenz, A., Murakami, J., Hofstetter, L., Abadi, U., Iyer, S., Mohamed, S., Miller, P. G., Natour, A. E. H., Weinstein, S., Yacobovich, J., Izraeli, S., Nikiforow, S., Ebert, B., Gurion, R., Cohen, I., Pasvolsky, O., Raanani, P., Nagler, A., Berliner, N., Daver, N., Ellis, M., Jordan, M.
Publicado 2022

PB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED/FRONTLINE BPDCN

por Pemmaraju, N., Martinelli, G., Todisco, E., Tarella, C., Montesinos, P., Lane, A. A., Erba, H. P., Sweet, K. L., Walter, R. B., Deconinck, E., Wang, E. S., Aribi, A., Ulrikson, M. L., Levy, M. Y., Lebon, D., Marconi, G., DeAngelo, D. J., Rizzieri, D., Konopleva, M., Sloss, C. M., Wang, J., Malcolm, K. A., Zweidler-McKay, P. A., Daver, N. G.
Publicado 2022